Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy
The addition of Nemvaleukin therapy may enhance responses to RT alone and in combination with anti-PD1.
Authors
- Zahid Rafiq (ORCID: https://orcid.org/0000-0001-7281-0780)
- Duygu Sezen (ORCID: https://orcid.org/0000-0002-4505-2280)
- Ethan Hsu
- Nahum Puebla‐Osorio (ORCID: https://orcid.org/0000-0001-6498-5230)
- Yun Hu (ORCID: https://orcid.org/0000-0001-5597-9234)
- Claudia S. Kettlun Leyton (ORCID: https://orcid.org/0000-0001-9158-6964)
- Ailing Huang
- Joshua Heiber
- Hampartsoum B. Barsoumian (ORCID: https://orcid.org/0000-0002-8209-6119)
- Kewen He (ORCID: https://orcid.org/0000-0003-0068-7191)
- Lily Jae Schuda
- James W. Welsh (ORCID: https://orcid.org/0000-0002-2255-8502)
- Thomas S. Riad
- Tiffany A. Voss
- Maria-Angelica Cortez
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Koç University (TR)
- Shandong Tumor Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2024-09-02
- DOI
- https://doi.org/10.1186/s13046-024-03165-x
- Citations
- 5
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.41
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province